 YARDLEY, Pa., June 2, 2021 PRNewswire -- Optinose NASDAQ:OPTN, a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat ENT and allergy specialists, today announced that the publication of a new stepped-care treatment algorithm in the International Forum of Allergy Rhinology, Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps, recommends Exhalation Delivery System-fluticasone EDS-FLU for the treatment of patients with nasal polyps. 